Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 12/20 | 0.45 |
| ▸ | PGR | P06401 | 2/20 | 0.43 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.38 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.37 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.36 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.36 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.36 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.36 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.36 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.36 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.36 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.35 |
| ▸ | FEN1 | P39748 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21116905 | 0.96 | AR (0.48) | ARPGRPTPN5TRPA1NR3C1 | |
| SCHEMBL21116904 | 0.93 | AR (0.45) | ARPGRPTPN5TRPA1NR3C1 | |
| SCHEMBL23798872 | 0.91 | AR (0.41) | ARPGRPTPN5NR3C1ALOX5AP | |
| SCHEMBL21116477 | 0.90 | AR (0.48) | ARPGRPTPN5NR3C1ESR2 | |
| SCHEMBL21116565 | 0.89 | AR (0.39) | ARPGR | |
| SCHEMBL20616986 | 0.86 | AR (0.48) | ARPGRPTPN5TRPA1NR3C1 | |
| SCHEMBL21116873 | 0.86 | TRPA1 (0.41) | ARPTPN5TRPA1NR3C1ESR2 | |
| SCHEMBL21116341 | 0.86 | SCN9A (0.43) | ARPGRTRPA1NR3C1ALOX5AP | |
| SCHEMBL21116487 | 0.85 | KIF11 (0.50) | ARPTPN5 | |
| SCHEMBL21116553 | 0.84 | KIF11 (0.40) | ARPGRPTPN5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11136294-B2 | Organic molecules for use in optoelectronic devices | CYNORA GMBH (DE) | 2021-10-05 | — | — | US | disclosed |
| EP-3478656-B1 | DICARBAZOLE DIPHENYL DERIVATIVES FOR USE IN OPTOPELECTRONIC DEVICES | CYNORA GMBH (DE) | 2021-09-08 | — | — | EP | disclosed |
| US-20190194130-A1 | ORGANIC MOLECULES FOR USE IN OPTOELECTRONIC DEVICES | CYNORA GMBH (DE) | 2019-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190194130-A1 | ORGANIC MOLECULES FOR USE IN OPTOELECTRONIC DEVICES | OR10J3, NOX3, ORC3 | AR 1096/4885PGR 2665/4885PTPN5 2951/4885 |
| US-11136294-B2 | Organic molecules for use in optoelectronic devices | OR10J3, ORC3, NOX3 | AR 1080/4885PGR 2701/4885PTPN5 2989/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.